Postvaccine Anti–SARS-CoV-2 Spike Protein Antibody Development in Kidney Transplant Recipients

Solid organ transplant recipients are at an elevated risk of severe coronavirus disease 2019 (COVID-19), and early reports also suggest impaired response after the first dose of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine series.1–3 Because of concerns about vaccine immunogenicity, all kidney transplant recipients at our center are recommended to undergo anti–SARS-CoV-2 spike protein IgG (“anti-spike antibody”) testing 2 to 6 weeks after completing their vaccination series in full.